Prognosis-modifying therapy in multiple sclerosis

Neurological Sciences

Volumn 21, Issue 4 SUPPL. 2, 2000, Pages

  Comi, G ^a   Colombo, B ^a   Martinelli, V ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; INTERFERON BETA SERINE; NEOPTERIN; RECOMBINANT INTERFERON;

CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG ACTIVITY; DRUG FORMULATION; HUMAN; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PROGNOSIS; RECURRENCE RISK; SIDE EFFECT;

EID: 0034490245     PISSN: 15901874     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100720070033     Document Type: Conference Paper

References (51)

1. Confavreux C, Aimard G, Devic M (1980) Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103:281-300
2. Weinshenker BG, Bass B, Rice GPA, Noseworthy J Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. Clinical course and disability. Brain 112:133-146
3. _ (1994) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 44:1537-1540
4. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BGW, Burks JS (1996) Management of patients receiving interferon beta-1b for multiple sclerosis. Neurology 46:12-18
5. Oger J, Freedman M (1999) Consensus statement of the Canadian MS Clinical Network on: the use of disease modifying agents in multiple sclerosis. Can J Neurol Sci 26:274-275
6. The IFNB MS Study Group (1993) Interferon beta 1B is effective in relapsing remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43:655-661
7. Paty DW, Li DKB for the UBC MS/MRI Study Group, the IFNB MS Study Group (1993) Interferon beta 1B is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo controlled trial. Neurology 43:655-661
8. Redlich PN et al (1991) Antibodies that neutralize human beta interferon biologic activity recognize a linear epitope: analysis by synthetic peptide mapping. Proc Natl Acad Sci USA 88:655-661
9. Jacobs Let al (1996) Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 39:285-294
10. PRISMS (Prevention of Relapses and Disability by Interferon B-1a Subcutaneously in Multiple Sclerosis) Study Group (1998) Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet 352:1498-1504
11. Pozzilli C et al (1996) Magnetic resonance imaging changes with recombinant human interferon beta-1a: a short term study in relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 61:251-258
12. The Once Weekly Interferon for MS Study Group (1999) Evidence of interferon beta-1a dose response in relapsing-remitting MS: The OWIMS Study. Neurology 53(4):679-686
13. European Study Group on Interferon Beta 1b in Secondary Progressive MS (1998) Placebo-controlled multicentre randomised trial of interferon beta-1b in the treatment of secondary progressive multiple sclerosis. Lancet 352:1491-1497
14. Miller DH, Molyneux PD, Barker GJ et al (1999) Effect of interferon beta 1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter randomized double-blind placebo-controlled trial. Ann Neurol 46:850-859
15. Goodkin D and the North American Study Group on Interferon Beta 1B in Secondary Progressive MS (2000) American Academy of Neurology, San Diego, May 2 2000, Late Breaking News, 004
16. Arnon R (1996) The development of COP 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett 50:1-15
17. Arnon R, Teiltelbaum D (1980) Desensitization of experimental allergic encephalomyelitis with synthetic peptide analogues. In: Davison AN, Cuzner ML (eds) The suppression of experimental allergic encephalomyelitis and multiple sclerosis. Academic, New York, pp 105-117
18. Bornstein MB, Miller A, Teitelbaum D et al (1982) Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 11:317-319
19. Bornstein MB, Miller A, Slagle S et al (1987) A pilot trial of COP 1 in exacerbating-remitting multiple sclerosis. New Engl J Med 317:408-414
20. Bornstein MB, Miller A, Slagle S et al (1991) A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology 41:533-539
21. Johnson KP, Brooks BR, Cohen JA et al (1998) Extended use of copolymer 1 maintains clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 50:701-708
22. Comi G, Filippi M, for The Copaxone MRI Study Group (1999) The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MRI in patients with relapsing-remitting multiple sclerosis (RRMS): a multi-centre, randomised, double-blind, placebo-controlled study extended by open-label treatment. Neurology 52[Suppl 2]:A289 (abstract)
23. Korczyn AD, Nisipeanu P (1996) Safety profile of copolymer 1: analysis of cumulative experience in the United States and Israel. J Neurol 243[Suppl 1]:S23-S26
24. Johnson KP, Brooks BR, Cohen JA et al and the Copolymer 1 Multiple Sclerosis Study Group (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of the phase III multicenter, double-blind, placebo-controlled trial. Neurology 45:1269-1276
25. Johnson KP, Teitelbaum D, Arnon R et al (1995) Antibodies to copolymer 1 do not interfere with its clinical effects. Ann Neurol 38:973 (abstract)
26. Weinshenker BG (1994) Natural history of multiple sclerosis. Ann Neurol 36[Suppl]:S6-11
27. Runmarker B, Andersen O (1993) Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116:117-134
28. Filippi M, Horsfield MA, Morissey SP, MacManus DG, Rudge P, McDonald WI, Miller DH (1994) Quantitative brain MRI lesion load predicts the course of clinically isolated syndromes suggestive of multiple sclerosis. Neurology 44(4):635-641
29. O' Riordan JI, Thompson AJ, Kingsley PE, MacManus DG, Kendall BE, Rudge P, McDonald WI, Miller DH (1998) The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 121:495-503
30. Brex PA, O' Riordan JI, Miszkiel KA, Moseley IF, Thompson AJ, Plant GT, Miller DH (1999) Multisequence MRI in clinically isolated syndromes and the early development of MS. Neurology 53:1184-1190
31. Sciacca FL, Ferri C, Vandenbroeck K, Veglia F, Gobbi C, Martinelli F, Franciotla D, Zaffaroni M, Marrosu M, Martino G, Martinelli V, Comi G, Canal N, Grimaldi LMG (1999) Relevance of interleukin 1 receptor antagonist intron 2 polymorphism in Italian MS patients. Neurology 52(9): 1896-1898
32. Fukazawa T, Yanagawa T, Kikuchi S, Yabe I, Sasaki H, Hamada T, Miyasaka K (1999) CTLA-4 gene polymorphism may modulate disease in Japanese multiple sclerosis patients. J Neurol Sci 171(1):49-55
33. Yu BM, Johnson MJ, Tuohy VK (1996) A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med 183:1777-1788
34. Thuoy VK, Weinstock-Guttman B, Kinkel RP (1997) Diversity and plasticity of self recognition during the development of multiple sclerosis. J Clin Invest 99:1682-1690
35. Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL (1997) Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 94:599-603
36. Whitaker JN, Beverly AL, Bartolucci AA, Mitchell GW, Bashir K, Goodwill J, Kachelhofer D (1999) Urinary myelin basic-protein-like material in patients with multiple sclerosis durin interferon beta-1b treatment. Arch Neurol 56:687-691
37. Lucchinetli CF, Bruck W, Rodriguez M, Lassmann H (1996) Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol 6:259-274
38. Lassmann H (1998) Neuropathology in multiple sclerosis: new concepts. Mult Scler 4(3):93-98
39. Tourbah A, Stievenart JL, Gout O, Fontaine B, Liblau R, Lubetzki C, Cabanis EA, Lyon-Caen O (1999) Localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis. Neurology 53(5):1091-1097
40. Sarchielli P, Presciutti O, Pelliccioli GP, Tarducci R, Gobbi G, Chiarini P, Alberti A, Vicinanza F, Gallai V (1999) Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normal-appearing white matter of multiple sclerosis patients. Brain 122 (Pt 3):513-521
41. Matthews PM, De Stefano N, Narayanan S, Francis GS, Wolinsky JS, Antel JP, Arnold DL (1998) Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol 18(3):327-336
42. Rocca MA, Mastronardo G, Rodegher M, Comi G, Filippi M (1999) Long-term changes of magnetization transfer-derived measures from patients with relapsing-remitting and secondary progressive multiple sclerosis. AJNR Am J Neuroradiol 20(5):821-827
43. Filippi M, Rocca MA, Minicucci L, Martinelli V, Ghezzi A, Bergamaschi R, Comi G (1999) Magnetization transfer imaging of patients with definite MS and negative conventional MRI. Neurology 52(4):845-848
44. Filippi M, Campi A, Colombo B, Pereira C, Martinelli V, Baratti C, Comi G (1996) A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 243(7):502-505
45. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L (1999) Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 53(8): 1698-1704
46. Dastidar R Laasonen T, Lehtimaki T, Ukkonen M, Peltola J. Erila T, Laasonen E, Elovaara I (1999) Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis. J Neurol Sci 165(1):36-42
47. van Waesberghe JH, Kampphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, Lycklama à Nijeholt, van der valk P, Polman C, Thompson AJ, Barkhof F (1999) Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 46:747-754
48. Beck RW, Cleary PA, Trobe JD et al ( 1993 ) The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. N Engl J Med 329:1764-1769
49. Optic Neuritis Study Group (1997) The 5-year risk of MS after optic neuritis. Experience of the optic neuritis treatment trial. Neurology 49:1404-1413
50. Jacobs L, Beck R, Simon J et al (2000) Results of a phase III trial of interferon beta-1a treatment in patients at high risk of developing multiple sclerosis. American Academy of Neurology, San Diego, May 2 2000, Late Breaking News, 002
51. tive of multiple sclerosis: a multi-center, randomized, double-blind, placebo-controlled study. Neurology 54(7):S3:A85